Navigation Links
Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
Date:7/15/2008

PRINCETON, N.J., July 15 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has entered into definitive agreements dated July 14, 2008 with a select group of institutional investors to sell 1,450,000 shares of its common stock in a "registered direct" offering. The investors have agreed to purchase the shares at a purchase price of $17.85 per share resulting in gross proceeds of approximately $25.9 million to Pharmasset, before deducting placement agent fees and estimated offering expenses. Morgan Stanley & Co. Incorporated, Canaccord Adams Inc., Cowen and Company, LLC and Leerink Swann LLC served as placement agents for the offering and Morgan Stanley acted as lead manager.

The shares described above are being offered by Pharmasset pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission on June 26, 2008. The transaction is expected to close on or about July 21, 2008, subject to customary closing conditions. Pharmasset intends to use the net proceeds from the sale of the shares for general corporate purposes, which include, but are not limited to, the acquisition of assets or businesses that are complementary to its existing business, the funding of clinical trials and the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by calling Morgan Stanley & Co. Incorporated, toll free, at 1-866-718-1649.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that the closing of the offering may not occur, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research ... Stem Cell (hESC) Research - Global Strategic Business Report" report ... ... Cell (hESC) Research in US$ Million. Annual estimates and forecasts are ... are derived from primary and secondary research. The ...
(Date:3/24/2017)...   Sienna Biopharmaceuticals, Inc. , a privately held, ... Richard Peterson will join the company as ... who brings more than two decades of global financial ... retiring at the end of April but will continue ... Sienna from Novan, Inc., where he served as Chief ...
(Date:3/23/2017)... , ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become ... hosted corporate cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, ... the reason for its increasing popularity is due to its new team building format, a ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):